Global Recombinant Protein Market

Recombinant Protein Market Size, Share, Growth Analysis, By Product (Cytokines & Growth Factors, Antibodies), By Application (Drug Discovery & Development, Biopharmaceutical Production), By Region - Industry Forecast 2024-2031

Report ID: SQMIG35H2039 | Region: Global | Published Date: July, 2024
Pages: 165 | Tables: 66 | Figures: 75

Recombinant Protein Market Competitive Landscape

There are several dominant players in the recombinant protein business. Several strategic activities, such as mergers, partnerships, alliances, new product launches, acquisitions, and collaborations, are being implemented by the firms to help them increase their international competitiveness. For instance, in February 2021, In order to determine the best antigen dosages for the Phase 3 evaluation of its adjuvanted recombinant protein COVID-19 vaccine candidates, Sanofi and GSK have begun a new Phase 2b trial with 720 individuals who are 18 years old & older.

Recombinant Protein Market Top Players Company Profiles 

  • Bio-Techne (US) 
  • Thermo Fisher Scientific Inc. (US) 
  • Merck KGaA (Germany) 
  • Danaher Corporation (US) 
  • Abnova Corporation (Taiwan) 
  • BioLegend Inc (US) 
  • Bio-Rad Laboratories, Inc. (US) 
  • BPS Bioscience, Inc. (US) 
  • Enzo Biochem Inc. (US) 
  • GenScript (China) 
  • Miltenyi Biotec B.V. & Co. KG (Germany) 
  • Proteintech Group, Inc. (US) 
  • Sino Biological Inc. (China) 
  • ACROBiosystems Group (US) 
  • Aviva Systems Biology Corporation (US) 
  • Sartorius CellGenix GmbH (Germany) 
  • Icosagen (US) 
  • Neuromics (US) 
  • ProSpec-Tany TechnoGene Ltd. (Israel) 
  • ProteoGenix S.A.S (France)

Recombinant Protein Market Recent Development

  • In September 2021, Aviva Systems Biology, a global key player in producing antibodies, ELISA tests kits, and recombinant proteins for scientific research, confirmed the introduction of its new protein on demand semi-custom recombinant protein portfolio for basic research and pre-clinical investigations.
$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Global Recombinant Proteins Market size was valued at around USD 2.20 billion in 2022 and is expected to rise from USD 2.36 billion in 2023 to reach a value of USD 4.11 billion by 2031, at a CAGR of 7.2% over the forecast period (2024–2031).

There are several dominant players in the recombinant protein business. Several strategic activities, such as mergers, partnerships, alliances, new product launches, acquisitions, and collaborations, are being implemented by the firms to help them increase their international competitiveness. For instance, in February 2021, In order to determine the best antigen dosages for the Phase 3 evaluation of its adjuvanted recombinant protein COVID-19 vaccine candidates, Sanofi and GSK have begun a new Phase 2b trial with 720 individuals who are 18 years old & older. 'Bio-Techne (US) ', 'Thermo Fisher Scientific Inc. (US) ', 'Merck KGaA (Germany) ', 'Danaher Corporation (US) ', 'Abnova Corporation (Taiwan) ', 'BioLegend Inc (US) ', 'Bio-Rad Laboratories, Inc. (US) ', 'BPS Bioscience, Inc. (US) ', 'Enzo Biochem Inc. (US) ', 'GenScript (China) ', 'Miltenyi Biotec B.V. & Co. KG (Germany) ', 'Proteintech Group, Inc. (US) ', 'Sino Biological Inc. (China) ', 'ACROBiosystems Group (US) ', 'Aviva Systems Biology Corporation (US) ', 'Sartorius CellGenix GmbH (Germany) ', 'Icosagen (US) ', 'Neuromics (US) ', 'ProSpec-Tany TechnoGene Ltd. (Israel) ', 'ProteoGenix S.A.S (France)'

Over the projected time frame, the antibody segment is projected to expand at an exponential rate. This process has attracted attention in recent years and several businesses have embraced it for use in a variety of applications. After a selection procedure for antibodies with the necessary qualities, the genes can be introduced into an expression system, and the antibodies can be generated in large amounts.

In 2022, North America accounted for the largest share of the global market, and this trend is expected to continue during the forecast. The rising prevalence of chronic diseases, growing R&D investments, increased research and government incentives, and the presence of manufacturing companies in the U.S. are all factors contributing to North America’s market development. 

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

Click here right-arrow
logo-images

Related Reports

Recombinant Vaccines Market
Buy Now GET FREE SAMPLE
Recombinant DNA Technology Market
Buy Now GET FREE SAMPLE
Protein Engineering Market
Buy Now GET FREE SAMPLE
Recombinant Coagulation Factors Market
Buy Now GET FREE SAMPLE
Alternative Protein Market
Buy Now GET FREE SAMPLE
Protein Therapeutics Market
Buy Now GET FREE SAMPLE
Protein Chip Market
Buy Now GET FREE SAMPLE
Microbial Protein Market
Buy Now GET FREE SAMPLE

Feedback From Our Clients

Global Recombinant Protein Market

Report ID: SQMIG35H2039

$5,300
BUY NOW GET FREE SAMPLE